Invitae has announced an expansion of its hereditary cancer testing menu. Testing will now include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma, and skin cancers (melanoma and basal cell nevus syndrome). In addition, the company is introducing three new focused panels based entirely on oncology management guidelines in breast, gynecologic, and colon cancer. Invitae is also offering epidermal growth factor receptor testing for patients with strong personal and family history of lung cancer. This expanded test menu is offered at the same price and with the same flexibility as all of Invitae's genetic tests, the company said in a statement.